Se-hoon Lee, a Professor at Samsung Medical Center, recently gained attention by publishing a study on Leclaza (lazertinib, Yuhan Corp), a domestic third-generation EGFR TKI (Tyrosine Kinase Inhibitor).

With the advent of another option to the global standard therapy option Tagrisso (osimertinib) increasing the number of treatment options to two and rendering choices difficult on-site, Dailpharm met with Lee to hear his thoughts on treatment strategies that should be implemented in the clinical field?

Sehoon Lee, MD, Professor of Hematology/Oncology at Samsung Medical Center, spoke at an event hosted by AstraZeneca on the 11thto evaluate the value of Tagrisso amid the growing number of tr